Anti-bacterial performance of azithromycin nanoparticles as colloidal drug delivery system against different gram-negative and gram-positive bacteria

Advanced Pharmaceutical Bulletin

Volumn 2, Issue 1, 2012, Pages 17-24

  Azhdarzadeh, Morteza ^a,b   Lotfipour, Farzaneh ^b,c   Zakeri Milani, Parvin ^b,d   Mohammadi, Ghobad ^e   Valizadeh, Hadi ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Azithromycin; Minimum inhibitory concentration.; Modified quasi emulsion solvent diffusion; Nanoparticle; PLGA

Indexed keywords

AZITHROMYCIN; NANOPARTICLE; POLYGLACTIN;

AGAR DIFFUSION; ANTIBACTERIAL ACTIVITY; ARTICLE; BROTH DILUTION; CLINICAL EFFECTIVENESS; COLLOIDAL DRUG DELIVERY SYSTEM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; DILUTION; DRUG DELIVERY SYSTEM; DRUG POTENCY; DRUG STRUCTURE; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; INHIBITION ZONE DIAMETER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHYSICAL CHEMISTRY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 84875912292     PISSN: 22285881     EISSN: 22517308     Source Type: Journal    
DOI: 10.5681/apb.2012.003     Document Type: Article

References (29)

1. Ge H, Hu Y, Jiang X, Cheng D, Yuan Y, Bi H, et al. Preparation, characterization, and drug release behaviors of drug nimodipine-loaded poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) amphiphilic triblock copolymer micelles. J Pharm Sci 2002; 91: 1463-73.
2. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009; 86: 215-223.
3. Jelvehgari M, Barar J, Valizadeh H, Shadrou S, Nokhodchi A. Formulation, characterization and in vitro evaluation of theophylline-loaded Eudragit RS 100 microspheres prepared by an emulsion-solvent diffusion/evaporation technique. Pharm Dev Technol 2010;16(6):637-44.
4. Jelvehgari M, Nokhodchi A, Rezapour M, Valizadeh H. Effect of formulation and processing variables on the characteristics of tolmetin microspheres prepared by double emulsion solvent diffusion method. Indian J Pharm Sci 2010; 72: 72-78.
5. Jelvehgari M, Zakeri-Milani P, Siahi-Shadbad MR, Loveymi BD, Nokhodchi A, Azari Z, et al. Development of pH-sensitive insulin nanoparticles using Eudragit L100-55 and chitosan with different molecular weights. AAPS PharmSciTech 2010; 11: 1237-1242.
6. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res 1997; 14: 1568-1573.
7. Hajdo L, Szulc AB, Klajnert B, Bryszewska M. Metabolic limitations of the use of nucleoside analogs in cancer therapy may be overcome by application of nanoparticles as drug carriers: A review. Drug Development Research 2010; 71: 383-394.
8. Sunderland CJ, Steiert M, Talmadge JE, Derfus AM, Barry SE. Targeted nanoparticles for detecting and treating cancer. Drug Development Research 2006; 67: 70-93.
9. Barrera DA, Zylstra E, Lansbury PT, Langer R. Synthesis and RGD peptide modification of a new biodegradable copolymer: poly(lactic acid-co-lysine). J Am Chem Soc 1993; 115: 11010-11011.
10. Esmaeili F, Hosseini-Nasr M, Rad-Malekshahi M, Samadi N, Atyabi F, Dinarvand R. Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles. Nanomedicine 2007; 3: 161-167.
11. Hou Z, Zhou C, Luo Y, Zhan C, Wang Y, Xie L, et al. PLA nanoparticles loaded with an active lactone form of hydroxycamptothecin: development, optimization, and in vitro-in vivo evaluation in mice bearing H22 solid tumor. Drug Development Research 2011;72(4):337-345.
12. Yadav KS, Chuttani K, Mishra AK, Sawant KK. Long circulating nanoparticles of etoposide using PLGA-MPEG and PLGA-pluronic block copolymers: characterization, drug-release, blood-clearance, and biodistribution studies. Drug Development Research 2010; 71: 228-239.
13. Fawaz F, Bonini F, Maugein J, Lagueny AM. Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: pharmacokinetics and in vitro antimicrobial activity. International Journal of Pharmaceutics 1998; 168: 255-259.
14. Fattal E, Youssef M, Couvreur P, Andremont A. Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. Antimicrob Agents Chemother 1989; 33: 1540-1543.
15. Italia JL, Yahya MM, Singh D, Ravi Kumar MN. Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone. Pharm Res 2009; 26: 1324-1331.
16. Zakeri-Milani P, Ghanbarzadeh S, Lotfipoor F, Milani M, Valizadeh H. Pharmacokinetic study of two macrolide antibiotic oral suspensions using an optimized bioassay procedure. Journal of Bioequivalence & Bioavailability 2010; 2: 111-115.
17. Zakeri-Milani P, Valizadeh H, Islambulchilar Z, Damani S, Mehtari M. Investigation of the intestinal permeability of ciclosporin using the in situ technique in rats and the relevance of P-glycoprotein. Arzneimittelforschung 2008; 58: 188-192.
18. Mohammadi G, Valizadeh H, Barzegar-Jalali M, Lotfipour F, Adibkia K, Milani M, et al. Development of azithromycin-PLGA nanoparticles: physicochemical characterization and antibacterial effect against Salmonella typhi. Colloids Surf B Biointerfaces 2010; 80: 34-39.
19. Jelvehgari M, Valizadeh H, Rezapour M, Nokhodchi A. Control of encapsulation efficiencyin polymeric microparticle system of tolmetin. Pharm Dev Technol 2010; 15: 71-79.
20. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Approved Standard M7-A5. 5th ed. Wayne, PA: NCCLS; 2000.
21. No HK, Young Park N, Ho Lee S, Meyers SP. Antibacterial activity of chitosans and chitosan oligomers with different molecular weights. International Journal of Food Microbiology 2002; 74: 65-72.
22. Valizadeh H, Nokhodchi A, Qarakhani N, Zakeri-Milani P, Azarmi S, Hassanzadeh D, et al. Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, lactose, sorbitol, dextrin, and Eudragit E100. Drug Dev Ind Pharm 2004; 30: 303-317.
23. Azarmi S, Farid J, Nokhodchi A, Bahari-Saravi SM, Valizadeh H. Thermal treating as a tool for sustained release of indomethacin from Eudragit RS and RL matrices. Int J Pharm 2002; 246: 171-177.
24. Valizadeh H, Zakeri-Milani P, Barzegar-Jalali M, Mohammadi G, Danesh-Bahreini MA, Adibkia K, et al. Preparation and characterization of solid dispersions of piroxicam with hydrophilic carriers. Drug Dev Ind Pharm 2007; 33: 45-56.
25. Lotfipour F, Nazemiyeh H, Fathi-Azad F, Garaei N, Arami S, Talat S, et al. Evaluation of Antibacterial Activities of Some Medicinal Plants from North-West Iran. Iranian journal of basic medicinal sciences 2008; 11: 80-85.
26. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003; 55: 329-347.
27. Dillen K, Bridts C, Van der Veken P, Cos P, Vandervoort J, Augustyns K, et al. Adhesion of PLGA or Eudragit/PLGA nanoparticles to Staphylococcus and Pseudomonas. Int J Pharm 2008; 349: 234-240.
28. Lboutounne H, Chaulet JF, Ploton C, Falson F, Pirot F. Sustained ex vivo skin antiseptic activity of chlorhexidine in poly(epsilon-caprolactone) nanocapsule encapsulated form and as a digluconate. J Control Release 2002; 82: 319-334.
29. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release 2002; 82: 105-114.